drugset / Trial / NCT02978482
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in combination with tremelimumab in Chinese Patients with Advanced Malignancies
Timeline
- Start
- 2016-12-01
- Primary completion
- 2018-01-28
- Completion
- 2020-11-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 1 mg/kg | Intravenous |